Cipla launches RT-Direct multiplex COVID-19 RT PCR test kit in India

12 May 2022 , 01:33 AM

Cipla announced the commercialisation of RT-Direct multiplex COVID-19 RT PCR Test kit in India in partnership with Genes2Me Pvt Ltd With this Cipla is expanding its diagnostics offering to bring more advance and innovative products Cipla will be responsible for the distribution of RT Direct kits in India and has commenced supply of the same This kit is validated at the Indian Council of Medical Research ICMR approved Centre It is based on the gold standard RT-PCR method with coverage of three target genes specific to SARS-COV-2 along with IC which is much advanced than others having 1 or 2 target genes This greatly increases the sensitivity of the RTPCR test RT-Direct test protocol does not require any RNA extraction process making it faster and helps deliver results in just 45 minutes It will also increase the throughput of any testing lab by threefold compared to the normal RT-PCR test protocol time of 120-150 minutes